Clinical Trials Search at Vanderbilt-Ingram Cancer Center
BRAF V600E-mutant Colorectal Cancer Study of Encorafenib Taken With Cetuximab Plus or Minus Chemotherapy (BREAKWATER)
Multiple Cancer Types
To evaluate whether encorafenib plus cetuximab (EC), alone or in combination with chemotherapy, can improve clinical outcomes relative to current standard of care chemotherapy in participants with previously untreated BRAF V600E-mutant mCRC
Colon,
Rectal
III
Eng, Cathy
NCT04607421
VICCGI2085
